Endoscopic treatment of biliary complications in left lobe living donor liver transplantation

Mehmet Ali Erdogan
Muhsin Murat Harputluoglu
Department of Gastroenterology,
Medical Faculty, Inonu University,
Malatya 44210, Turkey

Purpose: Almost all of the publications regarding the treatment of biliary complications after liver transplantation are related to biliary complications after right lobe living donor liver transplantation (LDLT) and cadaveric liver transplantation (LT). The number of publications regarding endoscopic treatment of biliary complications after left lobe LDLT is negligible. In this study, we aimed to present the results of endoscopic treatments applied in the management of biliary complications developed in left-lobe duct-to-duct LDLT patients.

Patients and methods: Between 2008 and 2018, patients with duct-to-duct anastomosis who underwent ERCP due to biliary complication after left lobe LDLT were included in the study. Clinical data included patient demographics, indications for LDLT, duration till the first ERCP after LDLT, number of ERCP procedures, ERCP indications (stricture or leak), and treatment outcomes, including the need for percutaneous and surgical interventions.

Results: Among 13 patients who underwent ERCP, 2 (15%) had biliary leakage and 11 (8%) had an anastomotic stricture. Our endoscopic success rate was 100% in patients with biliary stricture. Despite the implementation of ERCP on two patients with leakage, they died due to the biliary complication.

Conclusion: Our results suggest that endoscopic treatment methods are successful in the management of biliary stricture complication in patients with left lobe LDLT and duct-to-duct anastomosis. Although our findings show that endoscopic treatments fail when there is a leakage after left lobe LDLT, there is a need for further studies that include more patients to reach a definite conclusion.

Keywords: anastomotic stricture, biliary leakage, biliary stone, ERCP, liver transplantation

Introduction

Biliary complications develop in approximately 30% of the liver transplant patients and are associated with significant morbidity and mortality. Often, one or more of the biliary complications may be in the form of anastomotic stricture, biliary leakage, stone or debris. Biliary complication incidence after cadaveric liver transplantation is 10%–15%, while in living donor liver transplantations, this rate goes up to 37%. Living donor liver transplants are usually performed using the right lobe. Nearly all the publications related to the treatment of biliary complications after liver transplantation are focused on biliary complications that occur after right lobe living donor liver transplantation (LDLT) and cadaveric liver transplantation (LT). The number of publications regarding endoscopic treatments of biliary complications after left lobe LDLT is almost negligible.

In this study, we present the results of endoscopic treatments that we performed in the management of biliary complications developed in left lobe duct-to-duct LDLT patients.
Material and methods

We analyzed the patient records of the Liver Transplantation Institute of Inonu University between September 2008 and January 2018, retrospectively. In our center, some parameters are taken into account in the graft type decision-making process in liver transplantation. These parameters are the risk to the donor, the residual liver volume for the donor, the size of the recipient and the liver mass required. Left lobe grafts were preferred in patients who were not expected to pose a risk to the recipient and the donor. Patients, who underwent endoscopic retrograde cholangiopancreatography (ERCP) after left lobe LDLT, were included in our study. The study was approved by the ethics committee of our university (decision number 2018/16–36) and written informed consents for reaching medical histories and interventions were obtained from all patients.

Clinical data included patient demographics, indication for LDLT, number of ERCP procedures, ERCP indications (stricture or leak), time for the first ERCP after LDLT and treatment outcomes including the need for percutaneous and surgical interventions.

Every patient was evaluated at a multidisciplinary committee including transplant surgeons, radiologists and gastroenterologists, along with their clinical data and imaging including magnetic resonance (MRI) or percutaneous cholangiography prior to ERCP.

When there were cholangitis symptoms or elevation of liver function tests, biliary stricture was suspected to be the cause. Magnetic resonance cholangiopancreatography (MRCP)/computerized tomography (CT) or percutaneous cholangiography was used to diagnose the biliary strictures. ERCP was preferred to be the first choice in patients with duct-to-duct anastomosis, in case there were findings of biliary strictures. Percutaneous cholangiograms were routinely performed for clinical indications just prior to catheter removal in approximately 90 days after liver transplantation. We used diluted contrast reagent (iohexol, Omnipaque 300™, 647 mg iohexol/mL, GE Healthcare, Oslo, Norway) to confirm the presence of biliary complications during percutaneous cholangiography. ERCP was not performed in patients without duct-to-duct anastomosis. Two experienced gastroenterologists (M.M.H., and M.A.E.) performed ERCP using Olympus duodenoscopes (TJF 160, Olympus Optical Co., Ltd., Tokyo, Japan). During ERCP, we routinely performed endoscopic sphincterotomy in every patient. When biliary stricture was detected in cholangiography performed with contrast agent, a 0.025 or 0.035-inch guidewire (Jagwire, Boston Scientific, Natick, MA, USA) was inserted via the catheter into the intrahepatic bile ducts. Later, we dilated it using a bougie (7 and 10 French, Wilson-Cook Medical GI Endoscopy, Winston Salem, NC, USA), and/or a balloon catheter (4, 6, or 8 mm, Hurricane RX; Boston Scientific, USA). Then, Amsterdam-type biliary stents (7 and 10 French, 9–18 cm long, Boston Scientific) were placed across the stricture or anastomosis. ERCP and stent revision was performed every 3–6 months. We incrementally increased the diameter and number of the stent to treat the stricture in each session. In our center, minimum stenting time was approximately 18 months. After 18 months, all patients with stricture were especially evaluated for stentless follow-up by cholangiography during the ERCP procedure. When the stricture was treated, we removed the biliary stents and monitored the patient without stents and when the stricture persisted, re-dilatation and re-stenting was performed endoscopically.

In the cases where cholangiogram showed a biliary leakage in patients with duct-to-duct anastomosis, ERCP was preferred as a treatment modality. Figure 1 shows our treatment algorithm in the presence of biliary leakage. When biliary leakage was detected during ERCP, we inserted biliary stents to stop the leakage. When biliary stones were found on imaging or during ERCP, we extracted the stones with a balloon or basket catheter.

When ERCP was unsuccessful (failure to avoid stricture or persistent biliary complications despite dilatation and stent placement), our multidisciplinary team determined whether percutaneous transhepatic biliary interventions (PTBI) and/or surgical treatments were indicated. When endoscopic and percutaneous treatments failed, surgical treatment was offered as a final option. In this study, ERCP was considered successful when patients did not have PTBI, surgery or death due to a biliary complication at any time during follow-up after the first ERCP. The data were analyzed using SPSS version 16.0 (SPSS Inc, Chicago, IL, USA) after being entered manually.

Results

Total liver transplantation number during the study period was 1,810 (1,460 LDLT, 350 cadaveric). Thirty-two patients underwent left lobe LDLT, all remaining patients underwent right lobe LDLT. It was found that ERCP was performed on 13 patients having duct-to-duct anastomosis due to biliary complications, out of 32 left lobe LDLT patients. Six of these patients were male (46%) and their median age was 46 (21–70). Recipients had transplantations due to Hepatitis B in 4, cryptogenic in 3, autoimmune hepatitis in 2, Budd–Chiari syndrome in 1, primary sclerosing cholangitis...
in 1, congenital hepatic fibrosis in 1 and fulminant hepatic failure in 1. Of the 13 patients who underwent ERCP, 2 had biliary leakage (15%) and 11 had an anastomotic stricture (85%). In patients with anastomotic stricture, the median time till the first ERCP after transplantation was 17 (7–96) weeks. The median number of ERCP processes in patients with stricture was 4 (1–14). The stricture was accompanied by stones in 6 of the patients. The time passed till the first ERCP after transplantation was 14 weeks (8–20 weeks) in patients with leakage. ERCP was performed only once in two patients with leakage.

Biliary dilatation and stenting were performed on 6 patients with anastomotic stricture. The remaining 5 patients received stenting only. We decided to use these interventional approaches according to the degree of strictures. Serious strictures were first dilated with bougie and balloon and then a stent was applied. The stent was implanted in the first session in patients with less strictures. The biliary stone balloon was used to clean the stones. ERCP was successfully performed on all 11 patients with stricture, no PTBI or surgical treatment was needed. In these patients, the median follow-up period of the process after the first ERCP was 16 months (3–42). In 6 of the patients, stenting with ERCP is being performed once every 3 months. Five patients with stricture, are being monitored in a stent-free way for 2, 3, 5, 8 and 50 months, respectively. Only endoscopic sphincterotomy (EST) was performed on 1 patient who had developed a biliary leakage, whereas the other patient underwent endoscopic sphincterotomy (EST) and stenting. One of these patients underwent an abdominal washout surgery, and the other did not receive any treatment except for endoscopic treatment. Both patients died after two weeks of ERCP due to biliary sepsis (Table 1).

**Discussion**

In this study, the ERCP success rate in 11 patients, who underwent ERCP due to biliary stricture after left lobe LDLT, was 100%. None of these patients needed PTBI or surgical treatment due to the biliary problem. Despite the ERCP implementation, 2 patients who had biliary leakage died due to biliary complication.

Unlike in right lobe, a bile duct is usually encountered in left lobe graft. Therefore, duct-to-duct anastomosis in left lobe liver transplantation is easier. However, arterial feeding
of the biliary duct bifurcation is extremely complex. When the segment 4 artery anastomosis is sometimes neglected, ischemic changes may be seen in the bile ducts of the left lobe grafts. In addition, the right and upward growth of the graft after left LBLT makes it difficult to visualize duct-to-duct anastomosis with ERCP.

Cadaveric organ shortage is the most important problem in liver transplantation. However, nowadays different graft types are being used to overcome this major problem. Right-lobe is preferred most commonly during the living donor liver transplantation because it helps to meet the metabolic demands of a recipient. However, the donor morbidity and mortality after right lobe donation have remained a formidable challenge over the last two decades. Donor safety has become an important priority in LDLT. The risk of donor mortality with the left lobe donation is lower compared to right lobe. However, the use of these grafts has increased the frequency of biliary complications significantly. The rate of biliary complications was reported to be 47% in patients with left LBLT.

<table>
<thead>
<tr>
<th>Patients</th>
<th>Age</th>
<th>Sex</th>
<th>Etiology</th>
<th>Biliary complication</th>
<th>Time to the first ERCP (week)</th>
<th>ERCP procedure number</th>
<th>Endoscopic treatment</th>
<th>Surgery</th>
<th>Outcome and follow-up duration (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1</td>
<td>63</td>
<td>M</td>
<td>HBV</td>
<td>Leak</td>
<td>8</td>
<td>1</td>
<td>ST</td>
<td>AW</td>
<td>Death</td>
</tr>
<tr>
<td>Case 2</td>
<td>69</td>
<td>M</td>
<td>HBV</td>
<td>AST</td>
<td>60</td>
<td>4</td>
<td>BD, ST</td>
<td>WS (16) and SF (50) respectively</td>
<td></td>
</tr>
<tr>
<td>Case 3</td>
<td>52</td>
<td>F</td>
<td>HBV</td>
<td>Leak</td>
<td>20</td>
<td>1</td>
<td>EST</td>
<td>Death</td>
<td></td>
</tr>
<tr>
<td>Case 4</td>
<td>22</td>
<td>M</td>
<td>CC</td>
<td>AST, BS</td>
<td>64</td>
<td>5</td>
<td>BD, ST</td>
<td>WS (16) and SF (2)</td>
<td></td>
</tr>
<tr>
<td>Case 5</td>
<td>57</td>
<td>F</td>
<td>CC</td>
<td>AST, BS</td>
<td>96</td>
<td>13</td>
<td>BD, ST</td>
<td>WS (40) and SF (8) respectively</td>
<td></td>
</tr>
<tr>
<td>Case 6</td>
<td>21</td>
<td>F</td>
<td>CHF</td>
<td>AST</td>
<td>28</td>
<td>4</td>
<td>ST</td>
<td>WS (12)</td>
<td></td>
</tr>
<tr>
<td>Case 7</td>
<td>49</td>
<td>M</td>
<td>AIH</td>
<td>AST</td>
<td>9</td>
<td>3</td>
<td>ST</td>
<td>WS (10)</td>
<td></td>
</tr>
<tr>
<td>Case 8</td>
<td>32</td>
<td>F</td>
<td>FHF</td>
<td>AST</td>
<td>13</td>
<td>2</td>
<td>BD, ST</td>
<td>WS (6)</td>
<td></td>
</tr>
<tr>
<td>Case 9</td>
<td>29</td>
<td>F</td>
<td>AIH</td>
<td>AST, BS</td>
<td>13</td>
<td>4</td>
<td>ST</td>
<td>WS (16)</td>
<td></td>
</tr>
<tr>
<td>Case 10</td>
<td>42</td>
<td>F</td>
<td>PSC</td>
<td>AST, BS</td>
<td>10</td>
<td>9</td>
<td>BD, ST</td>
<td>WS (28) and SF (3)</td>
<td></td>
</tr>
<tr>
<td>Case 11</td>
<td>46</td>
<td>M</td>
<td>CC</td>
<td>AST, BS</td>
<td>7</td>
<td>14</td>
<td>ST</td>
<td>WS (42) and SF (5)</td>
<td></td>
</tr>
<tr>
<td>Case 12</td>
<td>35</td>
<td>F</td>
<td>BCS</td>
<td>AST, BS</td>
<td>17</td>
<td>11</td>
<td>ST</td>
<td>WS (30)</td>
<td></td>
</tr>
<tr>
<td>Case 13</td>
<td>70</td>
<td>M</td>
<td>HBV</td>
<td>AST</td>
<td>53</td>
<td>1</td>
<td>BD, ST</td>
<td>WS (3)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AIH, autoimmune hepatitis; AST, anastomotic stricture; AW, abdominal washout; BCS, Budd–Chiari syndrome; BD, biliary dilatation; BS, biliary stone; CC, cryptogenic cirrhosis; CHF, congenital hepatic fibrosis; ERCP, endoscopic retrograde cholangiopancreatography; EST, endoscopic sphincterotomy; FHF, fulminating hepatic failure; HBV, Hepatitis B virus; LDLT, living donor liver transplantation; PSC, primary sclerosing cholangitis; SF, stent-free; ST, stent; WS, with stent.

There is no established therapeutic algorithm for treatment of biliary complications after LDLT. However, endoscopic treatments, percutaneous transhepatic intervention, and surgery have been frequently used. Currently, non-surgical treatments have largely replaced surgery as the initial treatment of biliary complications. ERCP is the first choice treatment in the presence of duct-to-duct anastomosis in post-LDLT biliary complications because it is less invasive, safe, effective, and easily accessible. Percutaneous transhepatic interventions are subsequently considered in cases where the endoscopic treatments fail. Surgical treatments are more complicated. Therefore, these are considered as a rescue therapy when all other treatment methods prove to be unsuccessful.

In literature, the success rate of endoscopic treatment of biliary strictures after LDLT is 20%–100%. However, almost all of the publications related to this topic are about endoscopic treatment results after right lobe LDLT. Chan et al reported an endoscopic success rate of 75% for biliary stricture in 8 patients with LDLT. Nakaseko et al reported that a stent was applied to a bile duct using ERCP in a patient with left-side grafted having duct-to-duct anastomosis and biliary stricture, and a stricture was successfully treated using a combination of ERCP, PTBI, and magnet compression anastomosis methods in another non-visible bile duct with stricture. In our study; the frequency of biliary stricture after left lobe LDLT was 34% (11/32) and the success rate of ERCP in 11 patients who underwent ERCP due to stricture, was 100%. None of these patients needed PTBI or surgical treatment due to a biliary problem. All of the patients, who underwent ERCP due to stricture, are being followed-up with stent revisions at the moment except five. Our results show that endoscopic treatment methods are very successful in the management of biliary strictures.
of biliary stricture complications in patients with left lobe LDLT and duct-to-duct anastomosis.

Another biliary complication seen after LDLT is biliary leakage. The prevalence of bile leaks does not differ significantly between DDLT and LDLT and furthermore, the frequency is not affected by anastomosis type (duct-to-duct or hepaticojejunostomy). The incidence of bile leakage after transplantation has been reported to be 2%–25%. ERCP, along with sphincterotomy and biliary stent placement, has become the preferred method of diagnosing and treating biliary leakage with high success rates and low complication rates in the patients with duct-to-duct anastomotic LDLT. Wadhawan et al reported an endoscopic success rate of 82% (14/17 patients) in patients with biliary leakage after LDLT. Chan et al reported that endoscopic treatments were successful in more than 85% of biliary leakage patients. Elwir et al reported that ERCP was the only treatment modality in 19 (90%) out of 21 patients who underwent ERCP due to leakage after LDLT. Chok et al reported that half of the patients were successfully treated with endo-radiological method in a very small group of patients (n=12) after LDLT. Although endoscopic treatments have taken priority over surgical treatments in the treatment of biliary stricture, there is still a need for surgical treatments when there is leakage. In a meta-analysis of 2,812 LDLT patients, contrary to previous studies reporting high success rates of endoscopic treatments in biliary leakages, only 40 out of 268 patients with biliary leakage could be treated endoscopically, and most patients (101 patients) were reported to have undergone surgery. Similarly, it has been reported that primary surgical approach was implemented in more than 50% of patients with biliary leakage. The studies mentioned are not published on the treatment of patients with leakage after left lobe LDLT. In our study, the biliary leak rate was 6% (2/32) and was consistent with the literature. Only EST was applied to one of the 2 ERCP patients due to biliary leakage, and EST and stent were applied to the other. One of these patients underwent an abdominal washout surgery, whereas the other did not receive any treatment other than endoscopic treatment. Both patients died due to biliary sepsis after two weeks of ERCP. Mostly biliary leakage is diagnosed in the early postoperative period and is associated with significant mortality and morbidity. In one study, 19% of patients with biliary leakage were lost due to complications related to biliary leakage. The 2-year survival rate in patients with biliary leakage was reported to be 65%, whereas it was reported to be 85% in patients without biliary leakage. Our results suggest that endoscopic treatment is unsuccessful in left lobe LDLT patients with leakage. In addition, the fact that our case count is very low and that there is no data available in the literature regarding the treatment of leakages after left lobe LDLT makes it difficult to comment on the efficacy of endoscopic methods in managing this complication.

Conclusion
Our results suggest that endoscopic treatment methods are very successful in the management of biliary stricture complication in patients with left lobe LDLT and duct-to-duct anastomosis. Although our findings suggest that endoscopic treatments fail when there is leakage after left lobe LDLT, there is a need for studies that include more patients to reach to a definite conclusion.

Disclosure
The authors report no conflicts of interest in this work.

References